The company will prioritize later-stage R&D, including potential accelerated approval for a second anti-amyloid antibody, while replacing its CEO and cutting Aduhelm commercial operations and other costs.

The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

The Swiss giant has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.